Tuesday, October 20, 2026, 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Roche.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.
Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 10, 2026, 1 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.
Webinar presenter Jeffrey Gregg, MD, University of Nevada
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
January 2020—Qiagen announced a series of agreements that expand its immuno-oncology assets for future commercialization of novel companion diagnostics, in particular based on next-generation sequencing technology. The agreements include a collaboration with Tokyo-based Repertoire Genesis that will provide access to novel technologies for the development of T-cell/B-cell receptor repertoire assays for use on NGS systems.
January 2020—Biodesix announced it has been issued a patent for its Biodesix Collection Device. The device aims to improve ease of use in blood sample collection for diagnostic testing. The BCD, which is currently used with the Biodesix Nodify XL2 test, combines multiple sample processing steps, including specimen collection and reproducible sample separation with ambient shipping. The company plans to use the BCD in all proteomic testing and make the device available for purchase by labs and diagnostic companies for sample processing and testing.
January 2020—Fujirebio Diagnostics received FDA clearance for its Lumipulse G whole PTH assay for testing on the Lumipulse G1200 immunoassay platform. The assay can be used in the differential diagnosis of hypercalcemia and hypocalcemia resulting from calcium metabolism disorders. The fully automated assay has a reaction time of 30 minutes and uses a single test cartridge. It has demonstrated excellent precision with a coefficient of variation of ≤4.0 percent, the company reports.
January 2020—Veracyte and NanoString have entered into an agreement in which Veracyte has obtained exclusive worldwide rights to develop and commercialize diagnostic tests on NanoString’s nCounter Flex system.
January 2020—LGC Maine Standards released its Validate LP2 linearity and calibration verification kits for Roche Cobas analyzers. The kits evaluate apolipoprotein A (Apo-A1) and apolipoprotein B (Apo-B). Validate SP1 linearity and calibration verification kits, specifically targeted for Roche Cobas and Roche Cobas Integra analyzers, were also released. The kits evaluate α1-antitrypsin, complement C3, complement C4, immunoglobulin A, immunoglobulin G, immunoglobulin M, and transferrin. The Validate LP2 and SP1 kits are in a human serum matrix.
January 2020—Microbiologics has launched rifampicin-resistant Mycobacterium tuberculosis positive and negative control panels for quality control of MTB-RIF molecular assays and test methods. Features of the controls include separate positive and negative control products, positive control representing five common mutations to the rpoB gene associated with rifampicin resistance (L511P, H526Y, S531L, D516V, S522L), room-temperature storage, and inactivated microorganism pellets for in vitro diagnostic use.
January 2020—Qiagen’s QuantiFeron-TB Gold Plus has been added to the diagnostic catalog of the Stop TB Partnership’s Global Drug Facility. The GDF provides quality-assured tuberculosis medicines, diagnostics, and laboratory supplies to the public sector.
January 2020—The FDA authorized marketing of PerkinElmer’s GSP Neonatal Creatine Kinase-MM kit, the first test to aid in newborn screening for Duchenne muscular dystrophy.
January 2020—Oxford Gene Technology has developed the CytoSure NGS panel for the detection of loss of heterozygosity, mosaicism, copy number variants, single nucleotide variants, and indels. The solution features up-to-date content for intellectual disability and developmental delay, the targeted NGS panel, and Interpret software.
January 2020—DiaSorin Molecular has released a primer pair that targets Candida auris, for use in laboratory-developed molecular tests. Candida auris is often multidrug resistant and has caused recent outbreaks in hospitals and long-term care facilities across the U.S. and in more than 20 countries, the company reports. The primer pairs are classified as analyte-specific reagents, which can be used by high-complexity laboratories to develop their own LDTs. DiaSorin Molecular, 562-240-6500
